Eledon is a clinical-stage biotechnology company developing tegoprubart, an IgG1 anti-CD40L monoclonal antibody designed to prevent organ rejection and treat immune-mediated diseases by blocking CD40 Ligand signaling and promoting regulatory T cells. The company's lead program targets kidney transplant rejection prevention, with additional development in xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis, competing against major pharmaceutical firms with proprietary patents covering anti-CD40L antibodies and treatment methods extending to 2046. Eledon currently operates pre-revenue as a clinical-stage company, with revenue expected to depend on successful regulatory approval and market adoption of tegoprubart across transplantation and neurological indications.